Tech Company Financing Transactions
CuraSen Therapeutics Funding Round
On 10/18/2018, CuraSen Therapeutics announced $54.5 million in Series A funding from New Leaf Venture Partners, Alta Partners and Johnson & Johnson Development Corporation.
Transaction Overview
Company Name
Announced On
10/18/2018
Transaction Type
Venture Equity
Amount
$54,500,000
Round
Series A
Investors
Proceeds Purpose
This financing allows us to build an industry leading team and company to address a number of these diseases for which no effective treatments are available. CuraSen expects to advance its first program to the clinic by the end of 2019.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2655 Campus Dr. 110
San Mateo, CA 94403
USA
San Mateo, CA 94403
USA
Phone
Website
Email Address
Overview
CuraSen Therapeutics is focused on the discovery and development of therapies to treat neurodegenerative diseases, including Parkinson's Disease, Alzheimer's Disease and less common neurodegenerative disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Kathleen Glaub
Chief Executive Officer
Anthony Ford
Chief Medical Officer
Gabriel Vargas
Co-Founder
Robert Booth
Co-Founder
Mehrdad Shamloo
VP - Operations
Peter Butera
Browse more venture capital transactions:
Prev: 10/18/2018: Passport venture capital transaction
Next: 10/18/2018: Pr3vent venture capital transaction
Share this article
Where The Data Comes From
We record tech company VC transactions. All VC database entries reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs